COURT-RULING filed Mar 30, 2026 at 20:00 ET
In the long-running Lamictal reverse-payment antitrust case, the District Court for the District of New Jersey vacated a magistrate's order that had permitted five new expert reports from GSK and Teva without reviewing their content. The court found the magistrate's decision clearly erroneous and remanded for further proceedings, requiring the magistrate to assess whether the reports were within the scope of the scheduling order. This procedural setback for GSK increases uncertainty but does not resolve the underlying antitrust claims.